Tatva Chintan Pharma Chem Limited - Asset Resilience Ratio
Tatva Chintan Pharma Chem Limited (TATVA) has an Asset Resilience Ratio of 0.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Tatva Chintan Pharma Chem Limited to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Tatva Chintan Pharma Chem Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TATVA current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Tatva Chintan Pharma Chem Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Tatva Chintan Pharma Chem Limited (TATVA) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs53.09 Million | 0.58% |
| Total Liquid Assets | Rs53.09 Million | 0.58% |
Asset Resilience Insights
- Limited Liquidity: Tatva Chintan Pharma Chem Limited maintains only 0.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tatva Chintan Pharma Chem Limited Industry Peers by Asset Resilience Ratio
Compare Tatva Chintan Pharma Chem Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP |
Specialty Chemicals | 1.69% |
|
Cngr Advanced Material Co Ltd
SHE:300919 |
Specialty Chemicals | 0.52% |
|
Supreme Petrochem Limited
NSE:SPLPETRO |
Specialty Chemicals | 8.22% |
|
5N Plus Inc.
TO:VNP |
Specialty Chemicals | 12.56% |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930 |
Specialty Chemicals | 0.01% |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488 |
Specialty Chemicals | 1.39% |
|
Jiangxi Guotai Civilian
SHG:603977 |
Specialty Chemicals | 12.39% |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093 |
Specialty Chemicals | 25.17% |
Annual Asset Resilience Ratio for Tatva Chintan Pharma Chem Limited (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Tatva Chintan Pharma Chem Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.04% | Rs3.27 Million ≈ $35.36K |
Rs8.36 Billion ≈ $90.44 Million |
-1.23pp |
| 2024-03-31 | 1.27% | Rs103.64 Million ≈ $1.12 Million |
Rs8.19 Billion ≈ $88.54 Million |
-0.57pp |
| 2023-03-31 | 1.83% | Rs138.50 Million ≈ $1.50 Million |
Rs7.56 Billion ≈ $81.79 Million |
+1.71pp |
| 2022-03-31 | 0.12% | Rs8.02 Million ≈ $86.73K |
Rs6.58 Billion ≈ $71.19 Million |
-0.15pp |
| 2021-03-31 | 0.27% | Rs8.43 Million ≈ $91.17K |
Rs3.15 Billion ≈ $34.04 Million |
-0.17pp |
| 2020-03-31 | 0.44% | Rs10.92 Million ≈ $118.10K |
Rs2.49 Billion ≈ $26.92 Million |
-4.12pp |
| 2019-03-31 | 4.55% | Rs85.40 Million ≈ $923.57K |
Rs1.88 Billion ≈ $20.28 Million |
+3.63pp |
| 2018-03-31 | 0.93% | Rs13.38 Million ≈ $144.70K |
Rs1.44 Billion ≈ $15.62 Million |
-- |
About Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and br… Read more